Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by askretkaon Aug 17, 2022 8:01am
224 Views
Post# 34901440

RE:New here

RE:New here
15$ US target by HC Wainwright has existed since FEB of 2021. Target has never been downgraded. They value Breast cancer treatments at 1.6 Billion US. $ 8.50 CDN target by Douglas Loe is probably most detailed. His 2030 earnings model predictsearnings of over 6$ per share which at 20x earnings gives us a potential future value of over 120$ a share. So why is stock price so low? Oncolytics has a bit history of a troubled history and traders have made a lot of money buying and selling stock and shorting. Buying stock then selling after news. No big mystery there. It looks like things are about to change towards end of year or into 2023 Initial Pancreatic Cancer data on 3 patients shrunk tumors about 50% in 16 weeks. 10 year survival for Pancreatic is less than 5% with no real treatment options. Analysts want more data before adding Pancreatic Cancer to their price model but could be a game changer for the stock and Pancreatic Cancer patients. I think this is an investment opportunity of a lifetime but consider me biased and have been accumulating stock. Big blocks of stock are hard to buy now at times and stock can move on smaller volumes. Welcome to the board. Cheers!!!!!!!!
<< Previous
Bullboard Posts
Next >>